ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
7.94
-0.01 (-0.13%)
At close: Apr 28, 2026, 4:00 PM EDT
7.93
-0.01 (-0.13%)
After-hours: Apr 28, 2026, 7:12 PM EDT
ARS Pharmaceuticals Employees
As of December 31, 2025, ARS Pharmaceuticals had 163 total employees, including 158 full-time and 5 part-time employees. The number of employees increased by 3 or 1.88% compared to the previous year.
Employees
163
Change (1Y)
3
Growth (1Y)
1.88%
Revenue / Employee
$517,043
Profits / Employee
-$1,050,908
Market Cap
788.42M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 163 | 3 | 1.88% |
| Dec 31, 2024 | 160 | 134 | 515.38% |
| Dec 31, 2023 | 26 | 6 | 30.00% |
| Dec 31, 2022 | 20 | 11 | 122.22% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| MeiraGTx Holdings | 403 |
| Kura Oncology | 260 |
| Allogene Therapeutics | 152 |
| Cullinan Therapeutics | 109 |
| Theravance Biopharma | 90 |
| Alto Neuroscience | 68 |
| Crescent Biopharma | 44 |
SPRY News
- 13 days ago - neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) - GlobeNewsWire
- 4 weeks ago - ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label - GlobeNewsWire
- 6 weeks ago - ARS Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - ARS Pharmaceuticals Earnings Call Transcript: Q4 2025 - Transcripts
- 7 weeks ago - ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting - GlobeNewsWire
- 3 months ago - EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to - GlobeNewsWire